ArticleCancer medicine2019
Melanoma incidence, recurrence, and mortality in an integrated healthcare system: A retrospective cohort study.
Article in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Clinical, humanistic and economic burden associated with recurrence among patients with early-stage cancers: a systematic literature review.Frontiers in oncology · 2025Pooled it
- Clinical Practice Guidelines on Sentinel Lymph Node Biopsy for Melanoma: A Systematic Review and Quality Appraisal Using the AGREE II Instrument.Annals of surgical oncology · 2022Pooled it
- Racial Differences in the Prognosis and Survival of Cutaneous Melanoma From 1990 to 2020 in North America: A Systematic Review and Meta-Analysis.Journal of cutaneous medicine and surgeryPooled it
- Characteristics and overall survival in patients with T1 melanoma: A nationwide matched cohort study.International journal of cancer · 2026Article
- Recurrent melanoma presenting as a rash: a case report.Skin health and disease · 2025Article
- Clinicopathological Factors Predicting Melanoma Recurrence: A Study From South East Ireland.Dermatology practical & conceptual · 2025Article
- Management of In-transit Disease: Regional Therapies, Intralesional Therapies, and Systemic Therapy.Surgical oncology clinics of North America · 2025Review
- Identification of immune-related genes and integrated analysis of immune-cell infiltration in melanoma.Aging · 2024Article
- Temporal Recurrence of Cutaneous Melanoma: Analysis of a Case Series.The Journal of clinical and aesthetic dermatology · 2023Article
- Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study.Journal for immunotherapy of cancer · 2023Article
- Melanoma awareness and prevention among latinx and non-latinx white adults in urban and rural California: A qualitative exploration.Cancer medicine · 2023Article
- Prediction of early-stage melanoma recurrence using clinical and histopathologic features.NPJ precision oncology · 2022Article
- Proteasomal down-regulation of the proapoptotic MST2 pathway contributes to BRAF inhibitor resistance in melanoma.Life science alliance · 2022Article
- Article
- circITCH suppresses cell proliferation and metastasis through miR-660/TFCP2 pathway in melanoma.Cancer medicine · 2022Article
- Oncolytic viruses in melanoma.Frontiers in bioscience (Landmark edition) · 2022Review
- Assessment of the Novel, Practical, and Prognosis-Relevant TNM Staging System for Stage I-III Cutaneous Melanoma.Frontiers in oncology · 2022Article
- A Cohort Study: Comorbidity and Stage Affected the Prognosis of Melanoma Patients in Taiwan.Frontiers in oncology · 2022Article
- A study on skin tumor classification based on dense convolutional networks with fused metadata.Frontiers in oncology · 2022Article
- BRAF-Inhibitor-Induced Metabolic Alterations in A375 Melanoma Cells.Metabolites · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNumerous studies have examined melanoma incidence and survival, but studies on melanoma recurrence are limited. We examined melanoma incidence, recurrence, and mortality among members of Kaiser Permanente Colorado (KPCO) between January 1, 2000 and December 31, 2015.
methodsAge-adjusted incidence rates were computed to examine trends among KPCO members aged 21 years and older. Cox proportional hazards models were used to examine factors associated with recurrence and mortality.
resultsOur cohort included 1931 cases of invasive melanoma. Incidence rates increased over time and were higher than SEER rates; however, the increase was limited to early stage disease. In multivariable models, stage at initial diagnosis, gender, and age were associated with melanoma recurrence. Men were more likely to have a recurrence than women (adjusted hazard ratio [HR]: 1.70, 95% confidence interval [CI]: 1.19-2.43), and for each decade of increasing age, the adjusted HR = 1.20 (95% CI: 1.06-1.37). Factors associated with all-cause mortality included stage (HR = 12.87, 95% CI: 6.63-24.99, for stage IV vs stage I), male gender (HR = 1.42, 95% CI: 1.12-1.79), older age at diagnosis, lower socioeconomic status, and comorbidity index. For melanoma-specific mortality, results were similar, with one exception: age was not associated with melanoma-specific death (HR = 1.09, 95% CI: 0.94-1.25, P = 0.253).
conclusionsData derived from an insured patient population, such as KPCO, have the potential to enhance our understanding of emerging trends in melanoma. This is the first population-based study in the United States to examine patient characteristics associated with risk of recurrence. Men have an increased risk of both recurrence and death, and thus may benefit from more intensive follow-up than women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.